Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label trial to evaluate the safety, tolerability and immunological profile of
INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using
CELLECTRA® 2000 device in healthy adult volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Inovio Pharmaceuticals
Collaborators:
Coalition for Epidemic Preparedness Innovations Coalition for Epidemic Preparedness Innovations (CEPI)